Hodgkin Lymphoma , Non-Hodgkin Lymphoma
Dr. Saeed earned his MD at the University of Baghdad, College of Medicine, Iraq. He completed a post-doctoral fellowship at the University of Kentucky, College of Pharmacy, in Dr. Abeer Al-Ghananeem’s Lab. Dr. Saeed completed an Internal Medicine Residency and Hematology and Medical Oncology Fellowship, and he served as Chief Fellow at the University of Kentucky. Dr. Saeed joins us from the University of Kentucky, where he was appointed as an Assistant Professor in the Department of Internal Medicine, Division of Hematology and Blood and Marrow Transplantation, College of Medicine. Dr. Saeed specializes in treating blood cancers. His primary clinical focus includes the management of Non-Hodgkin’s and Hodgkin’s lymphomas. Dr. Saeed’s primary research expertise focuses on early phase clinical trials using novel chemotherapy combinations. He is also interested in understanding blood cancer characteristics and outcomes through population-based studies.
CLINICAL TRIAL 20361
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As A Single Agent In Relapsed Or Refractory Hematological Malignancies and In Combination With Daratumumab As A Salvage Regimen for Multiple Myeloma
Condition: Malignant Hematology
Intervention: Daratumumab (Darzalex); NKTR-255 (); Rituxan (rituximab); rituximab ()
CLINICAL TRIAL 20385
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin(Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Condition: Malignant Hematology
Intervention: Adcetris (Brentuximab vedotin); Adriamycin (doxorubicin); BMS-936558 (Nivolumab); Brentuximab vedotin (); DTIC (Dacarbazine); Dacarbazine (); Nivolumab (Opdivo); SGN-35 (Brentuximab vedotin); Velban (Vinblastine); Vinblastine (); doxorubicin ()
Rose A, Grajales-Cruz A, Lim A, Todd A, Bello C, Shah B, Chavez J, Pinilla-Ibartz J, Saeed H, Sandoval-Sus J, Isenalumhe L, Sokol L. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb.21(2):132-138. Pubmedid: 32950461.
Saeed H, Sokol L. Extranodal NK/T Cell Lymphoma: Evidence-based Review of Safety and Toxicity of the Available Regimens. Clin Lymphoma Myeloma Leuk. 2021 Apr.21(4):199-204. Pubmedid: 33129745.
Myint ZW, Shrestha R, Siddiqui S, Slone S, Huang B, Ramlal R, Monohan GP, Hildebrandt GC, Saeed H. Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: An analysis from Kentucky Cancer Registry. Hematol Oncol Stem Cell Ther. 2020 Mar.13(1):17-22. Pubmedid: 31629724.
Myint ZW, Oo TH, Thein KZ, Tun AM, Saeed H. Copper deficiency anemia: review article. Ann Hematol. 2018 Sep.97(9):1527-1534. Pubmedid: 29959467.
Saeed H, Yalamanchi S, Liu M, Van Meter E, Gul Z, Monohan G, Howard D, Hildebrandt GC, Herzig R. Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort. Hematol Oncol Stem Cell Ther. 2018 Jun.11(2):90-95. Pubmedid: 29398592.
Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017 Jun.28(6):1403. Pubmedid: 28368439.
Saeed H, Hnoosh D, Huang B, Durbin EB, McGrath PC, Desimone P, Maynard E, Anthony LB, Dineen SP, Hosein PJ, Tzeng CW. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. J Surg Oncol. 2016 Sep.114(4):451-455. Pubmedid: 27238300.
Saeed H, Woods RR, Lester J, Herzig R, Gul Z, Monohan G. Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting. Int J Hematol. 2015 Aug.102(2):195-199. Pubmedid: 25997871.
Saeed H, Awasthi M, Al-Qaisi A, Massarweh S. Blastic plasmacytoid dendritic cell neoplasm with extensive cutaneous and central nervous system involvement. Rare Tumors. 2014 Oct.6(4):5474. Pubmedid: 25568744. Pmcid: PMC4274438.
Chen L, Romond E, Chokshi S, Saeed H, Hodskins J, Stevens M, Pasley G, Weiss H, Massarweh S. A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation. Breast Cancer Res Treat. 2012 Nov.136(2):565-572. Pubmedid: 23053651.
Saeed H, Massarweh S. Images in clinical medicine. Hypertrophic pulmonary osteoarthropathy and tripe palms. N Engl J Med. 2012 Jan.366(4):360. Pubmedid: 22276825.
Al-Ghananeem AM, Saeed H, Florence R, Yokel RA, Malkawi AH. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target. 2010 Jun.18(5):381-388. Pubmedid: 20001275.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub